In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Regeneron has won a patent case against Swiss pharma giant Novartis over the delivery system for its eye drug Eylea.
The US Patent Trial and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
